Published in J Alzheimers Dis on January 01, 2009
Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Mol Neurodegener (2009) 1.18
Brain interstitial oligomeric amyloid β increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease. FASEB J (2013) 1.12
Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J Alzheimers Dis (2012) 1.04
Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases. J Alzheimers Dis (2010) 1.01
Caffeine extends life span, improves healthspan, and delays age-associated pathology in Caenorhabditis elegans. Longev Healthspan (2012) 1.00
Coffee intake in midlife and risk of dementia and its neuropathologic correlates. J Alzheimers Dis (2011) 0.93
Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier. Adv Drug Deliv Rev (2011) 0.91
The role of ryanodine receptor type 3 in a mouse model of Alzheimer disease. Channels (Austin) (2014) 0.87
Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. Life Sci (2014) 0.87
Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease. J Pharm Pharmacol (2011) 0.86
Gene-environment interaction research and transgenic mouse models of Alzheimer's disease. Int J Alzheimers Dis (2010) 0.85
Increased Cerebrospinal Fluid Production as a Possible Mechanism Underlying Caffeine's Protective Effect against Alzheimer's Disease. Int J Alzheimers Dis (2011) 0.84
Role of microglia adenosine A(2A) receptors in retinal and brain neurodegenerative diseases. Mediators Inflamm (2014) 0.80
Atorvastatin prevents amyloid-β peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway. Acta Pharmacol Sin (2014) 0.80
Coffee, but not caffeine, has positive effects on cognition and psychomotor behavior in aging. Age (Dordr) (2013) 0.79
Stuck at the bench: Potential natural neuroprotective compounds for concussion. Surg Neurol Int (2011) 0.78
Lifespan Extension Induced by Caffeine in Caenorhabditis elegans is Partially Dependent on Adenosine Signaling. Front Aging Neurosci (2015) 0.78
Choroidal Proteins Involved in Cerebrospinal Fluid Production may be Potential Drug Targets for Alzheimer's Disease Therapy. Perspect Medicin Chem (2011) 0.77
An overview on therapeutics attenuating amyloid β level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels. Am J Transl Res (2016) 0.76
Caffeine, Through Adenosine A3 Receptor-Mediated Actions, Suppresses Amyloid-β Protein Precursor Internalization and Amyloid-β Generation. J Alzheimers Dis (2015) 0.76
Protective effect of chronic caffeine intake on gene expression of brain derived neurotrophic factor signaling and the immunoreactivity of glial fibrillary acidic protein and Ki-67 in Alzheimer's disease. Int J Clin Exp Pathol (2015) 0.76
Redundant Gs-coupled serotonin receptors regulate amyloid-β metabolism in vivo. Mol Neurodegener (2016) 0.75
Having a Coffee Break: The Impact of Caffeine Consumption on Microglia-Mediated Inflammation in Neurodegenerative Diseases. Mediators Inflamm (2017) 0.75
Antroquinonol Lowers Brain Amyloid-β Levels and Improves Spatial Learning and Memory in a Transgenic Mouse Model of Alzheimer's Disease. Sci Rep (2015) 0.75
Purinergic receptors as potential therapeutic targets in Alzheimer's disease. Neuropharmacology (2015) 0.75
Caffeine and cognitive decline in elderly women at high vascular risk. J Alzheimers Dis (2013) 0.75
Altered motility of plaque-associated microglia in a model of Alzheimer's disease. Neuroscience (2016) 0.75
Caffeine Blocks HIV-1 Tat-Induced Amyloid Beta Production and Tau Phosphorylation. J Neuroimmune Pharmacol (2016) 0.75
Association between tea consumption and risk of cognitive disorders: A dose-response meta-analysis of observational studies. Oncotarget (2017) 0.75
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron (2005) 7.53
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev (1999) 6.26
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med (2006) 5.09
In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci (2003) 5.00
Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol (2006) 4.77
Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron (2008) 3.98
Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 2.78
Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr (2006) 2.72
Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol Aging (2008) 2.51
The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol (2005) 2.39
Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology (2006) 2.21
Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci (2002) 1.97
Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J Alzheimers Dis (2009) 1.91
Effects of caffeine on human health. Food Addit Contam (2003) 1.84
Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci (2004) 1.81
The relationship of coffee consumption with mortality. Ann Intern Med (2008) 1.65
Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res (2001) 1.59
Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience (2006) 1.53
The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology (2007) 1.47
Does caffeine intake protect from Alzheimer's disease? Eur J Neurol (2002) 1.46
Caffeine analogs: biomedical impact. Cell Mol Life Sci (2007) 1.41
Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp Neurol (2006) 1.23
Enhanced cognitive activity--over and above social or physical activity--is required to protect Alzheimer's mice against cognitive impairment, reduce Abeta deposition, and increase synaptic immunoreactivity. Neurobiol Learn Mem (2007) 1.22
Behavioral assessment of Alzheimer's transgenic mice following long-term Abeta vaccination: task specificity and correlations between Abeta deposition and spatial memory. DNA Cell Biol (2001) 1.22
Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. J Neuroinflammation (2008) 1.22
Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur J Clin Nutr (2006) 1.16
Antioxidant and prooxidant properties of caffeine, theobromine and xanthine. Med Sci Monit (2003) 1.04
A diet high in omega-3 fatty acids does not improve or protect cognitive performance in Alzheimer's transgenic mice. Neuroscience (2007) 1.03
Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. J Pharmacol Exp Ther (2005) 0.99
Arundic Acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. J Pharmacol Exp Ther (2006) 0.98
Abeta-specific T-cells reverse cognitive decline and synaptic loss in Alzheimer's mice. Neurobiol Dis (2006) 0.97
Caffeine suppresses TNF-alpha production via activation of the cyclic AMP/protein kinase A pathway. Int Immunopharmacol (2004) 0.97
Plasma Abeta levels do not reflect brain Abeta levels. J Neuropathol Exp Neurol (2007) 0.95
Caffeine: neuroprotective functions in cognition and Alzheimer's disease. Am J Alzheimers Dis Other Demen (2009) 0.92
Long-term treatment with some methylxanthines decreases the susceptibility to bicuculline- and pentylenetetrazol-induced seizures in mice. Relationship to c-fos expression and receptor binding. Eur J Neurosci (1996) 0.89
Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801. Exp Neurol (2007) 0.88
Use of multimetric statistical analysis to characterize and discriminate between the performance of four Alzheimer's transgenic mouse lines differing in Abeta deposition. Behav Brain Res (2004) 0.85
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Mapping and analysis of chromatin state dynamics in nine human cell types. Nature (2011) 24.37
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Res (2011) 16.53
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet (2012) 10.53
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science (2012) 10.42
The genome of the mesopolyploid crop species Brassica rapa. Nat Genet (2011) 8.23
Genomewide association study of leprosy. N Engl J Med (2009) 8.17
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA (2009) 7.78
Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron (2005) 7.53
Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med (2006) 7.14
National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke (2006) 6.94
Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature (2008) 6.89
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet (2009) 6.42
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
The role of apolipoprotein E in Alzheimer's disease. Neuron (2009) 5.55
Survival after initial diagnosis of Alzheimer disease. Ann Intern Med (2004) 5.52
Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat Neurosci (2011) 5.40
Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med (2006) 5.09
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J Neurosci (2003) 5.00
Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science (2009) 4.92
ApoE promotes the proteolytic degradation of Abeta. Neuron (2008) 4.75
Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol (2009) 4.71
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest (2004) 4.65
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol (2009) 4.59
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature (2009) 4.43
ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron (2004) 4.21
Comparative epigenomic analysis of murine and human adipogenesis. Cell (2010) 4.08
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med (2011) 4.07
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA (2008) 4.06
Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron (2008) 3.98
Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat Genet (2005) 3.98
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature (2012) 3.80
The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A (2005) 3.72
Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One (2010) 3.64
Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet (2009) 3.59
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Apolipoprotein E in Alzheimer's disease and other neurological disorders. Lancet Neurol (2011) 3.56
Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med (2012) 3.53
Systematic dissection and optimization of inducible enhancers in human cells using a massively parallel reporter assay. Nat Biotechnol (2012) 3.52
Selective vulnerability of late oligodendrocyte progenitors to hypoxia-ischemia. J Neurosci (2002) 3.50
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol (2013) 3.46
Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog (2010) 3.44
Aegilops tauschii draft genome sequence reveals a gene repertoire for wheat adaptation. Nature (2013) 3.40
apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest (2008) 3.36
Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab (2006) 3.35
The Arabidopsis CORONATINE INSENSITIVE1 protein is a jasmonate receptor. Plant Cell (2009) 3.31
Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology (2007) 3.22
Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med (2008) 3.15
Sleep quality and preclinical Alzheimer disease. JAMA Neurol (2013) 3.11
Complete genome sequence of Yersinia pestis strain 91001, an isolate avirulent to humans. DNA Res (2004) 2.95
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
Draft genome of the wheat A-genome progenitor Triticum urartu. Nature (2013) 2.86
Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A (2012) 2.84
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 2.81
Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 2.78
Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci (2009) 2.76
Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. Circ Res (2012) 2.74
Early pottery at 20,000 years ago in Xianrendong Cave, China. Science (2012) 2.73
Serotonin modulates the response of embryonic thalamocortical axons to netrin-1. Nat Neurosci (2007) 2.70
Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation (2005) 2.66
Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Sci Transl Med (2012) 2.66
Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2002) 2.58
Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver. Hepatology (2007) 2.53
Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science (2008) 2.53
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol (2012) 2.45
Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol (2013) 2.44
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition. Proc Natl Acad Sci U S A (2008) 2.44
Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem (2012) 2.42
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol (2009) 2.42
Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet (2010) 2.41
A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res (2008) 2.38
A comparative analysis of five methods of determining corneal refractive power in eyes that have undergone myopic laser in situ keratomileusis. Ophthalmology (2002) 2.37
Trends in stress urinary incontinence inpatient procedures in the United States, 1979-2004. Am J Obstet Gynecol (2009) 2.33
Multiobjective optimization design of a fractional order PID controller for a gun control system. ScientificWorldJournal (2013) 2.33
Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell (2013) 2.33
Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood (2006) 2.29
Loss of intranetwork and internetwork resting state functional connections with Alzheimer's disease progression. J Neurosci (2012) 2.26
Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol (2010) 2.25
The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc Natl Acad Sci U S A (2006) 2.23
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci (2005) 2.21
Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci (2009) 2.20
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology (2013) 2.19
ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem (2004) 2.19
Protein binding site prediction using an empirical scoring function. Nucleic Acids Res (2006) 2.19
Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci (2005) 2.17
LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med (2007) 2.17
Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. J Neurochem (2002) 2.13
GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron (2013) 2.13
Reversible and selective amine interactions of [Cd(mu2-N,O-p-NH2C6H4SO3)2(H2O)2]n. Dalton Trans (2004) 2.13